Microsoft vs ResMed Inc. — how do they compare? Microsoft trades at $396.33 (market cap $2.99T), while ResMed Inc. trades at $196 (market cap $28.81B). The key difference: Microsoft is far larger — about 103.8× ResMed Inc.'s market cap, and ResMed Inc. pays the higher dividend (1.21%). Which is the better fit depends on your goals.
| MSFT | RMD | |
|---|---|---|
Market Cap | $2.99T | $28.81B |
Volume | 36,654,621 | — |
Sector | Technology | Health |
52-Week High | $542.07 | $293.73 |
52-Week Low | $352.83 | $182.82 |
Enterprise Value | $2.97T | $27.99B |
Dividend Yield | 0.9% | 1.21% |
Signals from Pluang's Aura AI — not financial advice
Microsoft (MSFT) trades at $397.75, up 1.0% today, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $281.72B in 2025, with net income of $101.83B, and the company has beaten EPS estimates for three consecutive quarters. Analysts maintain an 80.49% buy rating with a consensus price target of $546.70, highlighting AI leadership through Azure and Copilot.
The outlook remains positive given robust earnings growth and AI-driven opportunities, but risks include elevated capital expenditure concerns and competitive pressures. Valuation metrics like a P/E of 23.96 and P/S of 9.43 suggest the stock is fairly priced, supporting a long-term bullish view tempered by near-term volatility.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →